Cancer is still a leading cause of death globally, with an estimated 20 million new cases and 10 million deaths each year. Immunotherapy has shown promise in treating previously untreatable cancers, but faces challenges. A key challenge is the lack of accurate preclinical models that mimic human immunity. To address this, the COST Action IMMUNO-model has established a network of researchers to develop and implement experimental models, aiming to improve the quality of life and survival rate of cancer patients. The network brings together over 250 researchers from 28 countries and focuses on a diverse array of experimental models to advance immunotherapy research and benefit cancer patients and society.
Source link
COST Action bridges the gap in cancer immunotherapy research
